Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AG Sequential NALIRIFOX for Unresectable Locally Advanced or Metastatic Pancreatic Cancer
ChiCTR2500110886Phase 4Not yet recruiting
- Sponsor
- Subei People's Hospital
- Start
- Oct 2025
- Modality
- Small Molecules, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of nanoliposomal irinotecan and nab-paclitaxel in pancreatic cancer (PC), sponsored by Subei People's Hospital. Primary endpoint: Overall survival. Planned start Oct 2025; status: not yet recruiting.
02
Drugs
nanoliposomal irinotecannab-paclitaxel
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on ChiCTR2500110886.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500110886.